178 related articles for article (PubMed ID: 28468758)
1. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.
Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490
[TBL] [Abstract][Full Text] [Related]
3. Dimorphism in the TCRγ-chain repertoire defines 2 types of human immunity to Epstein-Barr virus.
Djaoud Z; Parham P
Blood Adv; 2020 Apr; 4(7):1198-1205. PubMed ID: 32211881
[TBL] [Abstract][Full Text] [Related]
4. The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.
Pappworth IY; Wang EC; Rowe M
J Virol; 2007 Jan; 81(2):474-82. PubMed ID: 17079298
[TBL] [Abstract][Full Text] [Related]
5. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
6. [Anything that can go wrong: cytotoxic cells and their control of Epstein-Barr virus].
Gutiérrez-Guerrero A; Espinosa-Padilla SE; Lugo-Reyes SO
Rev Alerg Mex; 2024 Feb; 71(1):29-39. PubMed ID: 38683066
[TBL] [Abstract][Full Text] [Related]
7. EBV-induced T-cell responses in EBV-specific and nonspecific cancers.
Zhang Q; Xu M
Front Immunol; 2023; 14():1250946. PubMed ID: 37841280
[TBL] [Abstract][Full Text] [Related]
8. Transient reduction in IgA
van den Heuvel D; Jansen MA; Bell AI; Rickinson AB; Jaddoe VW; van Dongen JJ; Moll HA; van Zelm MC
J Leukoc Biol; 2017 Apr; 101(4):949-956. PubMed ID: 27821468
[TBL] [Abstract][Full Text] [Related]
9. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis.
Vietzen H; Berger SM; Kühner LM; Furlano PL; Bsteh G; Berger T; Rommer P; Puchhammer-Stöckl E
Cell; 2023 Dec; 186(26):5705-5718.e13. PubMed ID: 38091993
[TBL] [Abstract][Full Text] [Related]
10. Primary immunodeficiencies and the control of Epstein-Barr virus infection.
Palendira U; Rickinson AB
Ann N Y Acad Sci; 2015 Nov; 1356():22-44. PubMed ID: 26415106
[TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility to EBV-related disease.
Gandhi MK
Blood; 2023 Mar; 141(13):1499-1500. PubMed ID: 36995704
[No Abstract] [Full Text] [Related]
12. Normality sensing licenses local T cells for innate-like tissue surveillance.
McKenzie DR; Hart R; Bah N; Ushakov DS; Muñoz-Ruiz M; Feederle R; Hayday AC
Nat Immunol; 2022 Mar; 23(3):411-422. PubMed ID: 35165446
[TBL] [Abstract][Full Text] [Related]
13. Missing or altered self: human NK cell receptors that recognize HLA-C.
Hilton HG; Parham P
Immunogenetics; 2017 Aug; 69(8-9):567-579. PubMed ID: 28695291
[TBL] [Abstract][Full Text] [Related]
14. Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications.
Lawand M; Déchanet-Merville J; Dieu-Nosjean MC
Front Immunol; 2017; 8():761. PubMed ID: 28713381
[TBL] [Abstract][Full Text] [Related]
15. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression.
McHugh D; Caduff N; Barros MHM; Rämer PC; Raykova A; Murer A; Landtwing V; Quast I; Styles CT; Spohn M; Fowotade A; Delecluse HJ; Papoudou-Bai A; Lee YM; Kim JM; Middeldorp J; Schulz TF; Cesarman E; Zbinden A; Capaul R; White RE; Allday MJ; Niedobitek G; Blackbourn DJ; Grundhoff A; Münz C
Cell Host Microbe; 2017 Jul; 22(1):61-73.e7. PubMed ID: 28704654
[TBL] [Abstract][Full Text] [Related]
16. Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage.
Pugh JL; Nemat-Gorgani N; Norman PJ; Guethlein LA; Parham P
J Immunol; 2018 Feb; 200(3):1146-1158. PubMed ID: 29263215
[TBL] [Abstract][Full Text] [Related]
17. Licensing delineates helper and effector NK cell subsets during viral infection.
Zamora AE; Aguilar EG; Sungur CM; Khuat LT; Dunai C; Lochhead GR; Du J; Pomeroy C; Blazar BR; Longo DL; Venstrom JM; Baumgarth N; Murphy WJ
JCI Insight; 2017 May; 2(10):. PubMed ID: 28515356
[TBL] [Abstract][Full Text] [Related]
18. The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands.
Hilton HG; McMurtrey CP; Han AS; Djaoud Z; Guethlein LA; Blokhuis JH; Pugh JL; Goyos A; Horowitz A; Buchli R; Jackson KW; Bardet W; Bushnell DA; Robinson PJ; Mendoza JL; Birnbaum ME; Nielsen M; Garcia KC; Hildebrand WH; Parham P
Cell Rep; 2017 May; 19(7):1394-1405. PubMed ID: 28514659
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells as a promising tool to tackle cancer-A review of sources, methodologies, and potentials.
Preethy S; Dedeepiya VD; Senthilkumar R; Rajmohan M; Karthick R; Terunuma H; Abraham SJK
Int Rev Immunol; 2017 Jul; 36(4):220-232. PubMed ID: 28471248
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
